A Ray of Hope for Patients Battling Stubborn Multiple Myeloma – But Can This Game-Changing Combo Therapy Really Outshine the Rest?
Picture this: You're fighting a type of blood cancer called multiple myeloma, and it's not just staying put in your bone marrow – it's spreading to other parts of your body, forming tumors outside the bones. This is called extramedullary disease (EMD), and for patients who've tried and failed multiple standard treatments, it's a tough road. But emerging research is shining a light on a powerful duo: talquetamab and teclistamab. These drugs, when combined, are showing remarkable results in a hard-to-treat group. Intrigued? Let's dive into the latest findings from the RedirecTT-1 study, presented at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. And here's where it gets exciting – the data suggests this approach might outperform even the most advanced therapies out there. But is it too good to be true? Stick around as we unpack it all.
News Update: December 6, 2025
Key Clinical Insight
Study Group and Setup: This Phase 2 trial, known as RedirecTT-1, tested the combination of talquetamab (dosed at 0.8 mg/kg) and teclistamab (at 3.0 mg/kg), given subcutaneously every two weeks. It involved 90 patients with relapsed or refractory multiple myeloma (R/R MM) who had been exposed to three major classes of prior therapies – meaning they'd already tried the big guns like immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies. Crucially, all had true extramedullary disease, and the median follow-up period was 16.2 months. For beginners, think of R/R MM as a cancer that's come back after treatment or stopped responding, and extramedullary disease as tumors popping up in places like soft tissues, organs, or lymph nodes, making it even trickier to manage.
Effectiveness: The results were impressive. The overall response rate (ORR) – basically, how many patients saw their cancer shrink or disappear – hit 77.8% (with a 95% confidence interval of 67.8 to 85.9). Half of the patients achieved a complete response (CR) or better, meaning no detectable cancer. The 12-month duration of response (DOR) was 60.1%, progression-free survival (PFS) at 12 months was 55.6%, and overall survival (OS) stood at 73.8%. To put it simply, these stats show the treatment kept many patients alive and cancer-free for over a year. But here's the part most people miss: Responses were even stronger in those with smaller EMD tumors. Patients with tumor volumes under 25 cm² saw an ORR of 90.7% and CR rates of 60.5% or higher. As tumor size grew, results dipped slightly – to 66.7% ORR for 25-50 cm² and 65.4% for over 50 cm² – highlighting how early intervention might make a big difference.
Safety Profile: Safety was a bright spot, too. There were no severe cases of cytokine release syndrome (CRS), a common immune reaction where the body overreacts to treatment. Immune effector cell-associated neurotoxicity syndrome (ICANS), which can cause brain-related issues, occurred in just 12.2% of patients, and only 2.2% were severe. Common side effects included mostly mild taste changes (affecting 79%, like a metallic flavor in food), skin issues (69%, such as dryness), and nail changes (56%, like brittleness). More serious were grade 3/4 neutropenia (low white blood cell counts in 62.2%, raising infection risk) and infections (40% at grade 3/4). Overall, the combo proved manageable in this high-risk crowd, offering a balance of power and tolerability that could change lives.
In-Depth Analysis from the Experts
Dr. Saad Usmani from Memorial Sloan Kettering Cancer Center in New York shared these extended results at ASH 2025. The study focused on combining talquetamab (Tal) and teclistamab (Tec) for patients with triple-class exposed (TCE) R/R MM and true EMD. Patients received the drugs subcutaneously at the doses mentioned, every two weeks.
The analysis covered 90 individuals, with follow-up ranging from 0.5 to 23.7 months (median 16.2). Most (82.2%) had soft tissue involvement, like tumors in muscles or skin, while 32.2% affected organs such as the liver, and 18.9% involved lymph nodes. About 39% had non-secretory or oligo-secretory disease – meaning their cancer didn't produce much of the protein marker that doctors usually track – and 20% had tried BCMA-targeted CAR-T cell therapy before, which adds layers of resistance.
Efficacy metrics echoed the summary: 77.8% ORR (95% CI: 67.8-85.9), with 50% reaching CR or better. DOR couldn't be fully calculated yet, but the 12-month rate was 60.1%. PFS at 12 months: 55.6%; OS: 73.8%.
Breaking it down by EMD tumor volume:
- Under 25 cm²: 90.7% ORR (CI: 77.9-97.4), CR ≥60.5%.
- 25-50 cm²: 66.7% ORR (CI: 43.0-85.4), CR ≥52.4%.
- Over 50 cm²: 65.4% ORR (CI: 44.3-82.8), CR ≥30.8%.
For clarity, EMD tumor volume is like measuring the size of these rogue tumors – smaller ones respond better, which makes sense as the cancer hasn't overwhelmed the body yet.
Safety wise, it was well-tolerated: Zero grade 3+ CRS, 12.2% ICANS (2.2% severe). Top mild AEs: 79% taste changes, 69% skin events, 56% nail issues. Serious ones: 62.2% grade 3/4 neutropenia, 40% severe infections.
The team concluded: “With longer follow-up in patients with triple-class exposed relapsed/refractory multiple myeloma with true extramedullary disease, regardless of baseline tumor characteristics, talquetamab plus teclistamab efficacy exceeded all approved therapies, including T-cell redirecting and cellular therapies, noting limitations of cross-study comparisons.”
They added: “These data continue to highlight the clinical benefit of the novel combination of Tal + Tec in patients with true EMD, a population with high disease burden and significant unmet need.”
Source: Usmani S, Kumar S, Mateos MV, et al. Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up. December 6-9, 2025; Orlando, FL. Abstract: 698
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.
Related Stories
News: December 6, 2025
Emily Estrada
Manufacturing success for ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma patients right from the first relapse drops as more prior treatments are added, per insights shared at the 2025 ASH Annual Meeting & Exposition...
Manufacturing Success of Ciltacabtagene Autoleucel for Patients with Lenalidomide-Refractory Multiple Myeloma as Early as First Relapse Decreases with More Prior Lines of Therapy
December 6, 2025
Oncology
News: December 6, 2025
Emily Estrada
A multicenter study unveiled at the 2025 ASH Annual Meeting pinpointed major relapse indicators within 18 months of ciltacabtagene autoleucel treatment, aiding in refining strategies for high-risk relapsed/refractory multiple myeloma cases...
A Multicenter Analysis Presented at the 2025 ASH Annual Meeting Identified Key Predictors of Relapse Within 18 Months of Ciltacabtagene Autoleucel Infusion to Improve Treatment Strategy for Patients with High-Risk Relapsed/Refractory Multiple Myeloma
December 6, 2025
Oncology
News: December 6, 2025
Emily Estrada
Drawing from CARTITUDE-4 trial data showcased at the 2025 ASH Annual Meeting, ciltacabtagene autoleucel infusions delivered lasting responses and encouraging survival figures for standard-risk relapsed/refractory multiple myeloma...
Based on Results from the CARTITUDE-4 Study Presented at the 2025 ASH Annual Meeting, a Ciltacabtagene Autoleucel Infusion Achieved Durable Responses and Promising Survival Outcomes for Standard-Risk Relapsed/Refractory Multiple Myeloma
December 6, 2025
Oncology
Conference Coverage: December 1, 2025
Joshua Richter, MD
Joshua Richter, MD, discusses the sustained effectiveness of CAR T-cell therapy in multiple myeloma patients and stresses the importance of broader, fair access for everyone at the 2025 Lymphoma, Leukemia & Myeloma Congress...
Joshua Richter, MD, Shares Details on the Long-Term Efficacy of CAR T-Cell Therapy for Patients with Multiple Myeloma and Highlights the Need for Expanded, Equitable Access for All Patients at the 2025 Lymphoma, Leukemia & Myeloma Congress
December 1, 2025
Oncology
But Here's Where It Gets Controversial...
This study boldly claims the Tal+Tec combo outperforms all other approved treatments, including cutting-edge CAR-T therapies. Cross-trial comparisons can be tricky – like comparing apples to oranges – so is this a fair call? Critics might argue that while the data looks promising, we need head-to-head trials to confirm superiority. Plus, with side effects like neutropenia affecting over 60% of patients, should we prioritize this over alternatives with fewer risks? As we weigh the high unmet needs in EMD MM against potential downsides, it's worth pondering: Could this combination redefine standards, or are we overlooking hidden costs? What do you think – is this a game-changer worth the hype, or just another promising option in a sea of therapies? Do you agree it might surpass CAR-T for some patients, or disagree based on your experiences? Share your perspectives in the comments below – let's spark a discussion!
